Reports From the ESMO Asia Congress 2019
Episode description
This week, we summarize two studies presented at the recent ESMO Asia Congress—one on a novel combination therapy for unresectable liver cancer, and the second on the activity of a Chinese-manufactured trastuzumab biosimilar. We'll also discuss last week's FDA approval of acalabrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Acalabrutinib for CLL/SLL as Part of Project Orbis
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we summarize two studies presented at the recent ESMO Asia Congress—one on a novel combination therapy for unresectable liver cancer, and the second on the activity of a Chinese-manufactured trastuzumab biosimilar. We'll also discuss last week's FDA approval of acalabrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma.This week, we summarize two studies presented at the recent ESMO Asia Congress—one on a novel combination therapy for unresectable liver cancer, and the second on the activity of a Chinese-manufactured trastuzumab biosimilar. We'll also discuss last week's FDA approval of acalabrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Acalabrutinib for CLL/SLL as Part of Project Orbis
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:This week, we summarize two studies presented at the recent ESMO Asia Congress—one on a novel combination therapy for unresectable liver cancer, and the second on the activity of a Chinese-manufactured trastuzumab biosimilar. We'll also discuss last week's FDA approval of acalabrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Acalabrutinib for CLL/SLL as Part of Project Orbis
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> ESMO Asia 2019: Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular CarcinomaThis week, we summarize two studies presented at the recent ESMO Asia Congress—one on a novel combination therapy for unresectable liver cancer, and the second on the activity of a Chinese-manufactured trastuzumab biosimilar. We'll also discuss last week's FDA approval of acalabrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Acalabrutinib for CLL/SLL as Part of Project Orbis
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> ESMO Asia 2019: Trastuzumab Biosimilar HLX02 Shows Activity in HER2-Positive Metastatic Breast CancerThis week, we summarize two studies presented at the recent ESMO Asia Congress—one on a novel combination therapy for unresectable liver cancer, and the second on the activity of a Chinese-manufactured trastuzumab biosimilar. We'll also discuss last week's FDA approval of acalabrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Acalabrutinib for CLL/SLL as Part of Project Orbis
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Acalabrutinib for CLL/SLL as Part of Project Orbis